BioXcel Therapeutics (BTAI) EBIT Margin (2022 - 2026)
BioXcel Therapeutics' (BTAI) quarterly EBIT Margin came in at 4962.62% in Q1 2026, up 104869.0% year-on-year from N/an in Q1 2025, and down 23.56% quarter-over-quarter from 4016.41% in Q4 2025.
BioXcel Therapeutics (BTAI) EBIT Margin (2022 - 2026) Analysis & Trends
BioXcel Therapeutics' EBIT Margin history runs 5 years deep, the most recent figure standing at 4962.62% for Q1 2026.
- On a quarterly basis, EBIT Margin rose 104869.0% year-over-year to 4962.62% in Q1 2026; TTM through Mar 2026 was 7438.97%, a 456743.0% decrease from a year earlier, with the FY2025 full-year figure at 7859.97%, down 489240.0% from the prior year.
- EBIT Margin declined to 4962.62% in Q1 2026 per BTAI's latest filing, from 4016.41% in the prior quarter.
- Across five years, EBIT Margin topped out at 1566.67% in Q2 2024 and bottomed at 28459.85% in Q3 2022.
- The 5-year median for EBIT Margin is 7146.26% (2024), against an average of 10993.75%.
- Across the five-year window, EBIT Margin jumped 2070168 bps in 2024 and sank 1164333 bps in 2025, its largest moves.
- Year by year, EBIT Margin stood at 22224.37% in 2022, then soared by 76 bps to 5285.9% in 2023, then jumped by 46 bps to 2866.94% in 2024, then tumbled by 40 bps to 4016.41% in 2025, then decreased by 24 bps to 4962.62% in 2026.
- Per Business Quant, the three latest BTAI EBIT Margin figures stand at 4962.62% (Q1 2026), 4016.41% (Q4 2025), and 14518.37% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | BioXcel Therapeutics | 10.62 Mn | 10.62 Mn | -77,000.00 | -4,962.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4,962.62% |
| Dec 31, 2025 | -4,016.41% |
| Sep 30, 2025 | -14,518.37% |
| Jun 30, 2025 | -13,210.00% |
| Mar 31, 2025 | -6,011.31% |
| Dec 31, 2024 | -2,866.94% |
| Sep 30, 2024 | -7,146.26% |
| Jun 30, 2024 | -1,566.67% |
| Mar 31, 2024 | -4,151.72% |
| Dec 31, 2023 | -5,285.90% |
| Sep 30, 2023 | -14,163.34% |
| Jun 30, 2023 | -11,469.15% |
| Mar 31, 2023 | -24,853.40% |
| Dec 31, 2022 | -22,224.37% |
| Sep 30, 2022 | -28,459.85% |